Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis.

In the past decades, the oncogenic role of fibroblast growth factor receptor 2 has been demonstrated in a number of cancer types. However, studies have reported contradictory findings concerning the correlation between fibroblast growth factor receptor 2 expression and prognosis in solid tumors. To address this discrepancy, we performed a meta-analysis with 18 published studies (2975 patients) retrieved from PubMed, EMBASE, and Web of science. Data were extracted and computed into odds ratios. The results showed that fibroblast growth factor receptor 2 overexpression was significantly associated with decreased 3-year overall survival (odds ratio = 1.93, 95% confidence interval: 1.30-2.85, p = 0.001) and 5-year overall survival (odds ratio = 1.62, 95% confidence interval: 1.07-2.44, p = 0.02) in patients with solid tumors. Subgroup analysis revealed that high fibroblast growth factor receptor 2 expression was also associated with poor prognosis of gastric cancer, hepatocellular carcinoma, and esophageal cancer, but not correlated with pancreatic cancer. In conclusion, fibroblast growth factor receptor 2 overexpression is correlated with decreased survival in most solid tumors, suggesting that the expression status of fibroblast growth factor receptor 2 is a valuable prognostic biomarker and a novel therapeutic target in human solid tumors.

Repair of pressure ulcers in the elderly using autologous microskin implantation and negative pressure wound therapy: A retrospective study.

BACKGROUND: Pressure ulcers remain a worldwide problem. OBJECTIVE: To introduce an intermittent and feasible wound treatment method for the treatment of pressure ulcers in elderly patients. METHODS: This surgical procedure was performed on eight elderly patients suffering from pressure ulcers. Microskin measuring 0.1 × 0.1 centimeters was cut from a small amount of thin skin and then grafted onto the wound surface in conjunction with closed negative pressure therapy. RESULTS: Seven patients had their wounds closed after a single surgery, while one patient required two surgeries to close the wound. CONCLUSION: Autologous microskin implantation for the treatment of pressure ulcers in the elderly is an effective method to close the wound, which can prevent the elderly from living with wounds in their later years and is a viable treatment option.

Pediatric patients with familially inherited sitosterolemia: Two case reports.

Background: Sitosterolemia is a rare recessive genetic abnormality of hyperlipidemia; it is characterized by increased levels and accumulation of sitosterol in the plasma and local tissues. Case descriptions: The study subjects were two siblings (brother and sister) who had sitosterolemia with systemic multiple xanthomas as the main manifestation. The main clinical manifestations were hypercholesterolemia, premature atherosclerosis, arrhythmia, systemic multiple xanthomas, etc. After genetic testing, it was found that the patients had a compound heterozygous mutation of c.1324+1de1G in exon 7 and exon 9 of chromosome 2p21 of the adenosine triphosphate binding cassette transporter G family member 5(ABCG5) gene; the mutation at c.904+1G>A was of maternal origin, and the mutation at c. 1324+1de1G was of paternal origin. The compound heterozygous mutation of these two genes led to a metabolic disorder of plant sterols in vivo. Conclusion: Sitosterolemia is an autosomal recessive disease that could be effectively controlled after dietary control and oral lipid-lowering therapy with Ezetimibe. Xanthomas, which affects function and appearance, could be surgically removed, and primary wound healing could be achieved.

Wound Management of Multi-Site Pressure Ulcer at Different Stages in Elderly Patients.

OBJECTIVE: The present study aims to explore the individualized treatment options for multisite pressure ulcer (PU) at various stages in elderly patients with multiple medical conditions. METHODS: Stages 1 and 2 PU at 146 sites were treated with closed negative pressure suction combined with continuous micro-oxygen perfusion and the local application of foam dressings, silver ion dressings, and moist burn cream. Stages 3 and 4 PU in the sacrococcygeal region were treated with skin or myocutaneous flap transplantation. RESULTS: Stages 1 and 2 PU healed after treatment with closed negative pressure suction combined with continuous micro-oxygen perfusion and dressing changes. One case died during hospitalization due to an illness. Skin or myocutaneous flap repair was conducted in 34 cases of stage 3 or 4 PU in the sacrococcygeal area. Of these cases, 28 achieved primary healing, and 6 required two or three surgeries, 5 of which received micro-skin implantation. In addition, 10 small deep PU at other sites were repaired by direct excision and suturing or local flap repair. Seven cases were transferred to other departments or hospitals due to concomitant diseases or were discharged automatically without surgical treatment. CONCLUSION: Home care for geriatric patients is difficult. PU often occur at multiple sites because of the duration of various pressures, and different sites may demonstrate different stages because of varying degrees of pressure. When actively treating stages 3 and 4 PU, the trauma management of stages 1 and 2 PU should not be neglected.

Comparing a Right- Versus Left-Side Approach in Laparoscopy-Assisted D2 Radical Gastrectomies in Overweight Patients with Gastric Cancer: A Retrospective Case-Controlled Study.

BACKGROUND: The safety and efficacy of the surgical path used in laparoscopy-assisted radical gastrectomies (LARGs) is still unknown in obese patients. This study aimed to compare the value of a right-side (R-LARG) versus a left-side (L-LARG) approach in LARGs in overweight patients (defined as a body mass index (BMI) ≥ 25 kg/m2). METHODS: 213 patients with gastric cancer were divided into 2 groups: an overweight group and a normal-weight group (BMI < 25 kg/m2). Clinical characteristics and perioperative outcomes were compared in the 2 groups. RESULTS: In the overweight group, patients who underwent R-LARG had a shorter operating time (204 ± 15 vs. 248 ± 21 min), less intraoperative blood loss (66 ± 8 vs. 78 ± 7 ml), less painkiller usage (2.0 ± 0.2 vs. 2.5 ± 0.3 days), shorter time to mobility (2.1 ± 0.3 vs. 2.7 ± 0.5 days), faster recovery of peristalsis (3.4 ± 0.3 vs. 4.1 ± 0.5 days) and more lymph node dissection per patient (37 ± 4 vs. 31 ± 2) compared with the patients who underwent L-LARG. No statistically significant differences in postoperative complications (11.9% vs. 10.8%), postoperative hospital stays or hospitalization expenses were found between the groups. In the normal-weight group, perioperative outcomes were similar between the R-LARG and L-LARG groups. CONCLUSION: R-LARG has obvious advantages in overweight patients with gastric cancer.

CDC20 overexpression leads to poor prognosis in solid tumors: A system review and meta-analysis.

BACKGROUND: A plenty of previous researches have reported the prognostic value of CDC20 (Cell Division Cycle Protein 20) in solid tumors. Nevertheless, these researches were restricted by the small sample databases and the results were not strongly consistent among them. METHODS: We comprehensively searched these relevant studies by PubMed, Web of Science, and EMBASE, in which publications before March 2017 were included. Pooled HR values for OS were cumulatively pooled and quantitatively analyzed in the meta-analysis. RESULTS: Hence we composed a meta-analysis based on 8 studies with 1856 patients in order to assess the potential relationship between CDC20 overexpression and OS (overall survival) in human solid tumors. There were a total of 8 studies (n = 1856) assessed in the meta-analysis. What suggested in both univariate and multivariate analysis for survival is that high level of CDC20 expression apparently pointed to poor prognosis. In the univariate analysis, the combined hazard ratio (HR) for OS was 1.75 (95% confidence interval [CI]: 1.07-2.86, P = .03). The pooled HR of multivariate analysis for OS was 2.48 (95% confidence interval [CI]: 2.10-2.94, P < .001). CONCLUSIONS: The meta-analysis indicated that high level of CDC20 expression is significantly correlated with decreased survival in most case of human solid tumors. In addition, CDC20 shows promise as a meaningful prognostic biomarker and original therapeutic target, on the basis of its expression level in solid tumors.

Correction: NLRP6 targeting suppresses gastric tumorigenesis via P14ARF-Mdm2-P53-dependent cellular senescence.

[This corrects the article DOI: 10.18632/oncotarget.22876.].

Overexpression of COUP­TFII suppresses proliferation and metastasis of human gastric cancer cells.

The abnormal expression of the chicken ovalbumin upstream promoter transcription factor 2 (COUP­TFII) is associated with numerous forms of cancer, including gastric, prostate, colon and lung cancer. However, previous studies investigating the association between COUP­TFII expression and the occurrence, recurrence, invasion and metastasis of gastric cancer are limited in number. In the present study, it was revealed that the expression of COUP­TFII is significantly reduced in gastric carcinoma tissues compared with normal gastric mucosa cells (GES­1). In addition, the expression of COUP­TFII was also reduced in gastric cancer cell lines compared with GES­1 cells. Furthermore, it was revealed that ectopic expression of COUP­TFII was able to suppress the proliferation, migration and invasion of gastric cells, as well as inhibit hepatic metastasis, in vivo. In addition, it was demonstrated that COUP­TFII knockdown was able to promote the proliferation, migration and invasion of GES­1 cells in vitro. Furthermore, database analysis suggested that COUP­TFII expression in patients with gastric cancer is correlated with clinical stage classification and increased expression levels of COUP­TFII improved overall survival rates in patients with gastric cancer. The results of the present study suggest that COUP­TFII functions as a significant regulatory suppressor of gastric cancer growth and metastasis, and suggests that COUP­TFII may serve as a novel diagnostic and prognostic biomarker for gastric cancer metastasis.

Totally laparoscopic verse laparoscopic assisted distal gastrostomy for gastric cancer: an update meta-analysis.

Totally laparoscopic distal gastrostomy (TLDG) and laparoscopic- assisted distal gastrostomy (LADG) are the minimally invasive surgical technology for gastric cancer. This study aimed to compare the surgical outcomes of these two methods. Relevant studies were selected through electronic searches of EMBASE, PubMed and Web of Science. In total, 21 non-randomized controlled studies containing 2475 patients in the totally laparoscopic distal gastrostomy and 1889 patients in the laparoscopic-assisted distal gastrostomy were included in this study. And operative time, operative blood loss, retrieved lymph nodes, time to liquid diet (days), postoperative hospital stay and overall complications were pooled and compared using meta-analysis. There were no significant differences between operative time (WMD = 0.38, 95% CI -10.43 -11.18, P = 0.95) and overall complications (RR = 1.09, 95% CI 0.91-1.30, P = 0.36). But totally laparoscopic distal gastrostomy had more advantages in aspects of intraoperative blood loss (WMD = 24.4, 95% CI 12.45-36.36, P < 0.0001), time to liquid diet (days) (WMD = 0.21, 95% CI 0.03-0.40, P = 0.03) and postoperative hospital stay (WMD = 0.72, 95% CI 0.31-1.13, P = 0.0006). Moreover, totally laparoscopic distal gastrostomy had more retrieved lymph nodes (WMD = -1.24, 95% CI-1.90 to-0.58, P = 0.0002). This meta-analysis indicates that totally laparoscopic distal gastrostomy may be a safe, feasible, and favorable surgical technology in terms of less blood loss, faster liquid diet, shorter postoperative hospital stay and more lymph nodes retrieved.

Poor prognosis and SATB1 overexpression in solid tumors: a meta-analysis.

BACKGROUND: Several previous studies have reported the prognostic value of special AT-rich sequence-binding protein 1 (SATB1) in solid tumors. However, these studies produced inconsistent results because of their various limitations, including small sample sizes. Here, we describe a meta-analysis based on 17 studies including 3144 patients to search for connections between SATB1 overexpression and overall survival (OS) of patients with solid tumors. Seventeen studies (n = 3144) were assessed in the meta-analysis. Both univariate and multivariate analysis for survival indicated that high SATB1 reactivity significantly predicted poor prognosis. In the multivariate analysis, the combined hazard ratio (HR) for OS was 1.82 (95% confidence interval [CI]: 1.59-2.08, P < 0.0001). The pooled HR of the univariate analysis for OS was 1.96 (95% CI: 1.65-2.34, P < 0.0001). METHODS: Studies were identified by an electronic search of PubMed, EMBASE, and Web of Science, including publications prior to April 2017. Pooled HR values for OS were aggregated and quantitatively analyzed in the meta-analysis. CONCLUSION: The meta-analysis indicated that high SATB1 reactivity is significantly correlated with decreased survival in most cases of solid tumors. In addition, SATB1 shows promise as a prognostic biomarker and novel therapeutic target on the basis of its expression level in solid tumors.

Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis.

The prognostic significance of Ki-67 in patients with gastric cancer (GC) remains controversial. The aim of our meta-analysis is to evaluate its association with clinicopathological characteristics and prognostic value in patients with GC. PubMed, EMBASE, and Web of Science were systematically searched up to May 2017. Twenty-two studies including 3,825 patients with GC were analyzed. The meta-analysis indicated that the incidence difference of Ki-67 expression in GC patients was significant when comparing the older group to younger group (odds ratio [OR] =1.44, 95% confidence interval [CI] 1.19, 1.75), lymph node positive group to negative group (OR =1.49, 95% CI 1.20, 1.84), the large size tumor group to the small size tumor group (OR =1.27, 95% CI 1.24, 1.68) and the TNM stage III+IV group to TNM stage I+II group (OR =2.28, 95% CI 1.66, 3.12). However, no statistical differences existed in gender. The detection of Ki-67 significantly correlated with the overall survival of patients (hazard ratio =1.51, 95% CI 1.31, 1.72). Our study suggested that Ki-67 overexpression was associated with poor prognosis in GC patients. Ki-67 positive rates may be associated with age, lymph node metastasis, tumor size, and TNM staging system in GC patients.

Prognostic role of DEK in human solid tumors: a meta-analysis.

Recently, the oncogenic role of DEK has been recognized in several cancer types. However, its prognostic role in human solid tumor remains unclear. Thus, the present meta-analysis, based on 14 published studies (2208 patients) searched from PubMed, Web of Science, and EMBASE databases, assessed the prognostic value of DEK in human solid tumors. Furthermore, the pooled hazard ratio (HR) for overall survival (OS) was evaluated with fixed-effects models. A subgroup analysis was also performed according to the patients' ethnicities and tumor types. Data from these published studies were extracted, and the results showed that the overexpression of DEK was significantly associated with poor OS in human solid tumors. The combined hazards ratio was (HR = 1.83; 95% CI, 1.64-2.05, P < 0.00001) for OS (univariable analysis) with a fixed-effects model without any significant heterogeneity (P = 0.71, I2 = 0%). The combined HR was (HR = 1.70; 95% CI, 1.48-1.96, P < 0.00001) for OS (multivariable analysis) with a fixed-effects model, and no significant heterogeneity was observed (P = 0.36, I2 = 9%). Therefore, the overexpression of DEK was correlated with poor survival in human solid tumors, which suggests that the expression status of DEK is a valuable biomarker for the prediction of prognosis and serves as a novel therapeutic target in human solid tumors.

LRP6 targeting suppresses gastric tumorigenesis via P14ARF-Mdm2-P53-dependent cellular senescence.

NLRP6, a member of the Nod-like receptor family, protects against chemically induced intestinal injury and colitis-associated colon cancer. However, the cellular mechanisms involved in this NLRP6-mediated protection remain unclear. Here, we show that NLRP6 was down-regulated in approximately 75% of primary gastric cancer cases and exhibited significant associations with advanced clinical-stage lymph node metastasis and poor overall survival. Functional studies established that ectopic overexpression or down-regulation of NLRP6 inhibited cancer cell proliferation by inducing cell cycle arrest at the G1 phase via P21 and Cyclin D1 both in vitro and in vivo. Activation of the P14ARF-P53 pathway played a crucial role in the observed cellular senescence. We further demonstrated that ectopic overexpression of NLRP6 combined with inactivation of NF-κB(p65) and Mdm2 activates P14ARF-P53 to promote the senescence of gastric cancer cells. These findings indicate that NLRP6 functions as a negative regulator of gastric cancer and offer a potential new option for preventing gastric cancer.